Subscribe

Home » Investors » Subscribe

Contact

e-mail: info@ziccum.com

ZICCUM AB
Scheelevägen 22
223 63 LUND
Sweden

About us

Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and also are highly suitable for novel administration routes.

Subscribe

Receive company data continuously to your inbox